Clinical development of experimental virus-mediated gene therapy for malignant glioma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 739-747

  Rainov, Nikolai G ^a   Heidecke, Volkmar ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

Adeno associated virus; Adenovirus; Astrocytoma; Convection enhanced delivery; Glioblastoma; Glioma; Herpes simplex virus; Newcastle disease virus; Reovirus; Retrovirus

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CYTOSINE DEAMINASE; FLUOROURACIL; G 207; GANCICLOVIR; HSV 1716; NEWCASTLE DISEASE VIRUS HUJ; NEWCASTLE DISEASE VIRUS MTH 68/H; ONCOLYTIC PARAMYXOVIRUS; ONCOLYTIC VIRUS; ONYX 015; PARVOVIRUS VECTOR; PROTEIN P53; REOLYSIN; RETROVIRUS VECTOR; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APHASIA; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CLINICAL EFFECTIVENESS; DIGESTIVE SYSTEM CANCER; DRUG ACTIVATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; EXTERNAL BEAM RADIOTHERAPY; FEVER; GENE EXPRESSION; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEMIPARESIS; HERPES SIMPLEX VIRUS 1; HUMAN; INTRACRANIAL HYPERTENSION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); NEOPLASM; NEUROLOGIC DISEASE; NEUROTOXICITY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REOVIRUS; RETROVIRUS; RETROVIRUS VIRUS PRODUCING CELL; REVIEW; SINGLE DRUG DOSE; TRANSGENE; TREATMENT OUTCOME; TROPISM; TUMOR NECROSIS; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 80053466604     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378724     Document Type: Review

References (82)

1. Kleihues, P.; Cavenee, W.K. Pathology and genetics of tumours of the nervous system, 2nd ed.; IARC Press: Lyon, 2000.
2. Ohgaki, H.; Kleihues, P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol., 2005, 64, 479-489.
3. Davis, F.G.; Freels, S.; Grutsch, J.; Barlas, S.; Brem, S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J. Neurosurg., 1998, 88, 1-10.
4. Davis, F.G.; McCarthy, B.J.; Berger, M.S. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central brain tumor registry of the United States, surveillance, epidemiology, and end results, and National cancer data base. Neurooncol., 1999, 1, 205-211.
5. Swanson, K.R.; Alvord, E.C. Jr.; Murray, J.D. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br. J. Cancer, 2002, 86, 14-18.
6. Burton, E.C.; Prados, M.D. Malignant gliomas. Curr. Treat. Options Oncol., 2000, 1, 459-468.
7. Janus, T.J.; Kyritsis, A.P.; Forman, A.D.; Levin, V.A. Biology and treatment of gliomas. Ann. Oncol., 1992, 3, 423-433.
8. Salcman, M. Malignant glioma management. Neurosurg. Clin. N. Am., 1990, 1, 49-63.
9. Schiffer, D.; Cavalla, P.; Dutto, A.; Borsotti, L. Cell proliferation and invasion in malignant gliomas. Anticancer Res., 1997, 17, 61-69.
10. Guha, A.; Mukherjee, J. Advances in the biology of astrocytomas. Curr. Opin. Neurol., 2004, 17, 655-662.
11. Mitchell, P.; Ellison, D.W.; Mendelow, A.D. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol., 2005, 4, 413-422.
12. Whittle, I.R. Surgery for gliomas. Curr. Opin. Neurol., 2002, 5, 663-669.
13. Giese, A.; Westphal, M. Treatment of malignant glioma: a problem beyond the margins of resection. J. Cancer Res. Clin. Oncol., 2001, 127, 217-225.
14. Hess, C.F.; Schaaf, J.C.; Kortmann, R.D.; Schabet, M.; Bamberg, M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother. Oncol., 1994, 30, 146-149.
15. Giese, A.; Bjerkvig, R.; Berens, M.E.; Westphal, M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol., 2003, 21, 1624-1636.
16. DeAngelis, L.M. Brain tumors. N. Engl. J. Med., 2001, 344, 114-123.
17. Schiff, D.; Shaffrey, M.E. Role of resection for newly diagnosed malignant gliomas. Expert Rev. Anticancer Ther., 2003, 3, 621-630.
18. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987-996.
19. Kleinberg, L.R.; Weingart, J.; Burger, P.; Carson, K.; Grossman, S.A.; Li, K.; Olivi, A.; Wharam, M.D.; Brem, H. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest., 2004, 22, 1-9.
20. Chiocca, E.A.; Broaddus, W.C.; Gillies, G.T.; Visted, T.; Lamfers, M.L. Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J. Neurooncol., 2004, 69, 101-117.
21. Rainov, N.G.; Kramm, C.M. Vector delivery methods and targeting strategies for gene therapy of brain tumors. Curr. Gene Ther., 2001, 1, 367-383.
22. Zlokovic, B.V.; Apuzzo, M.L. Cellular and molecular neurosurgery: pathways from concept to reality - part II: vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery, 1997, 40, 805-813.
23. Pulkkanen, K.J.; Yla-Herttuala, S. Gene therapy for malignant glioma: current clinical status. Mol. Ther., 2005, 12, 585-598.
24. Coffey, M.C.; Strong, J.E.; Forsyth, P.A.; Lee, P.W. Reovirus therapy of tumors with activated Ras pathway. Science, 1998, 282, 1332-1334.
25. Rainov, N.G.; Kramm, C.M.; Aboody-Guterman, K.; Chase, M.; Ueki, K.; Louis, D.N.; Harsh, G.R.; Chiocca, A.; Breakefield, X.O. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther., 1996, 3, 99-106.
26. Csatary, L.K.; Gosztonyi, G.; Szeberenyi, J.; Fabian, Z.; Liszka, V.; Bodey B., Csatary, C.M. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol., 2004, 67, 83-93.
27. Freeman, A.I.; Zakay-Rones, Z.; Gomori, J.M.: et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther., 2006, 13, 221-228.
28. Lech, P.J.; Russell, S.J. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev. Vacc., 2010, 9, 1275-1302.
29. Forsyth, P.; Roldan, G.; George, D.; Wallace, C.; Palmer, C.A.; Morris, D.; Cairncross, G.; Matthews, M.V.; Markert, J.; Gillespie, Y.; Coffey, M.; Thompson, B.; Hamilton, M. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol. Ther., 2008, 16, 627-632.
30. Lal, R.; Harris, D.; Postel-Vinay, S.; de Bono, J. Reovirus: rationale and clinical trial update. Curr. Opin. Mol. Ther., 2009, 11, 532-539.
31. Meijer, D.H.; Maguire, C.A.; LeRoy, S.G.; Sena-Esteves, M. Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther., 2009, 16, 664-671.
32. Oldfield, E.H.; Ram, Z.; Culver, K.W.; Blaese, R.M.; DeVroom, H.L.; Anderson, W.F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene. Ther., 1993, 4, 39-69.
33. Rainov, N.G.; Ren, H. Gene therapy for human malignant brain tumors. Cancer J., 2003, 9, 180-188.
34. Muldoon, L.L.; Kroll, R.A.; Pagel, M.A.; Roman-Goldstein, S.; Fiamengo, S.A.; Neuwelt, E.A. Delivery of therapeutic genes to brain and intracerebral tumors. In: Gene therapy for neurological disorders and brain tumors; Chiocca, E.A.; Breakefield, X.O.; Eds.; Humana Press; Boston, 1997, pp. 128-39.
35. Ram, Z.; Culver, K.W.; Oshiro, E.M.; Viola, J.J.; DeVroom, H.L.; Otto, E.; et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med., 1997, 3, 1354-1361.
36. Dachs, G.U.; Hunt, M.A.; Syddall, S.; Singleton, D.C.; Patterson, A.V. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules, 2009, 14, 4517-4545.
37. Greco, O.; Dachs, G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol., 2001, 187, 22-36.
38. Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 1986, 46, 5276-5281.
39. Harsh, G.R.; Deisboeck, T.S.; Louis, D.N.; Hilton, J.; Colvin, M.; Silver, J.S.; Qureshi, N.H.; Kracher, J.; Finkelstein, D.; Chiocca, E.A.; Hochberg, F.H. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. Neurosurgery, 2000, 92, 804-811.
40. Ram, Z.; Barnett, G.; Vogelbaum, M.; Constantini, S.; Lillehei, K.; Sherman, J.; Fleming, C.; Westphal, M.; Mehdorn, M.; Puri, R. Pre-operative infusion of IL13-PE38QQR cytotoxin by convectionenhanced delivery (CED) in recurrent malignant glioma: A phase I/II study. Proc. Am. Soc. Clin. Oncol., 2003, 22, 403.
41. Andreansky, S.; Soroceanu, L.; Flotte, E.R.; Chou, J.; Markert, J.M.; Gillespie, G.Y.; et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res.,1997, 57, 1502-1509.
42. Chiocca, E.A. Oncolytic viruses. Nat. Cancer. Rev., 2002, 2, 938-951.
43. Dirven, C.; Van Beusechem, V.; Lamfers, M.; Grill, J.; Gerritsen, W.R.; Vandertop, W.P. Oncolytic adenoviruses for treatment of brain tumours. Expert Opin. Biol. Ther., 2002, 2, 943-952.
44. Heise, C.; Kirn, D.H. Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest., 2000, 105, 847-851.
45. Rainov, N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 2000, 11, 2389-2401.
46. Freeman, S.M.; Abboud, C.N.; Whartenby, K.A.; Packman, C.H.; Koeplin, D.S.; Moolten, F.L.; et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 1993, 53, 5274-5283.
47. Klatzmann, D.; Valery, C.A.; Bensimon, G.; Marro, B.; Boyer, O.; Mokhtari, K.; et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Hum. Gene Ther., 1998, 9, 2595-2604.
48. Shand, N.; Weber, F.; Mariani, L.; Bernstein, M.; Gianella-Borradori, A.; Long, Z.; Sorensen, A.G.; Barbier, N. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum. Gene Ther., 1999, 10, 2325-2335.
49. Izquierdo, M.; Cortes, M.L.; Martin, V.; de Felipe, P.; Izquierdo, J.M.; Pérez-Higueras, A.; Paz, J.F.; Isla, A.; Blázquez, M.G. Gene therapy in brain tumours: implications of the size of glioblastoma on its curability. Acta Neurochir. Suppl., 1997, 68, 111-117.
50. Izquierdo, M.; Martin, V.; de Felipe, P.; Izquierdo, J.M.; Pérez-Higueras, A.; Cortés M.L.; Paz, J.F.; Isla, A.; Blázquez, M.G. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther., 1996, 3, 491-495.
51. Prados, M.D.; McDermott, M.; Chang, S.M.; Wilson, C.B.; Fick, J.; Culver, K.W.; Van Gilder, J Keles, G.E Spence, A Berger, M. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vectorproducer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J. Neurooncol., 2003, 65, 269-278.
52. Puumalainen, A.; Vapalahti, M.; Agrawal, R.S.; Kossila, M.; Laukkanen, J.; Lehtolainen, P.; Viita, H.; Paljärvi, L.; Vanninen, R. ß-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther., 1998, 9, 1769-1774.
53. Trask, T.W.; Trask, R.P.; Aguilar-Cordova, E.; Shine, H.D.; Wyde, P.R.; Goodman, J.C.; Hamilton, W.J.; Rojas-Martinez, A.; Chen, S.H.; Woo, S.L.; Grossman, R.G. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther., 2000, 1, 195-203.
54. Judy, K.D.; Eck, S.L. The use of suicide gene therapy for the treatment of malignancies of the brain. In: Gene therapy of cancer; Lattime, E.C.; Stanton, L.C., Eds.; Academic Press: San Diego, 2002; pp 505-512.
55. Germano, I.M.; Fable, J.; Gultekin, S.H.; Silvers, A. Adenovirus/ herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J. Neurooncol., 2003, 65, 279-289.
56. Smitt, P.S.; Driesse, M.; Wolbers, J.; Kros, M.; Avezaat, C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol. Ther., 2003, 7, 851-858.
57. Martinez, J.D.; Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy. Future Oncol., 2010, 6, 1857-1862.
58. Lang, F.F.; Bruner, J.M.; Fuller, G.N.; Aldape, K.; Prados, M.D.; Chang, S.; Berger, M.S.; McDermott, M.W.; Kunwar, S.M.; Junck, L.R.; Chandler, W.; Zwiebel, J.A.; Kaplan, R.S.; Alfred Yung, W.K. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol., 2003, 21, 2508-2518.
59. Chiocca, E.A.; Smith, K.M.; McKinney, B.; Palmer, C.A.; Rosenfeld, S.; Lillehei, K.; Hamilton, A.; DeMasters, B.K.; Judy, K.; Kirn D. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol. Ther., 2008, 16, 618-626.
60. Sandmair, A.M.; Loimas, S.; Puranen, P.; Immonen, A.; Kossila, M.; Puranen, M.; Hurskainen, H.; Tyynelä, K.; Turunen, M.; Vanninen, R.; Lehtolainen, P.; Paljärvi, L.; Johansson, R.; Vapalahti, M.; Ylä-Herttuala, S. Thymidine kinase gene therapy for human malignant glioma; using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther., 2000, 11, 2197-2205.
61. Immonen, A.; Vapalahti, M.; Tyynela, K.; Hurskainen, H.; Sandmair, A.; Vanninen, R.; Langford, G.; Murray, N.; Ylä-Herttuala, S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised; controlled study. Mol. Ther., 2004, 10, 967-972.
62. http://www.dg-gt.de/docs/CereproPhase.pdf (Accessed Sept. 2010).
63. Mitchell, P. Ark's gene therapy stumbles at the finish line. Nat. Biotech., 2010, 28, 183-184.
64. Mineta, T.; Rabkin, S.D.; Yazaki, T.; Hunter, W.D.; Martuza, R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1995, 1, 938-943.
65. Markert, J.M.; Medlock, M.D.; Rabkin, S.D.; Gillespie, G.Y.; Todo, T.; Hunter, W.D.; lmer, C.A.; Feigenbaum, F.; Tornatore, C.; Tufaro, F.; Martuza, R.L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 2000, 7, 867-874.
66. Markert, J.M.; Parker, J.N.; Gillespie, G.Y.; Whitley, R.J. Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes, 2001, 8, 17-22.
67. Harland, J.; Papanastassiou, V.; Brown, S.M. HSV1716 persistence in primary human glioma cells in vitro. Gene Ther., 2002, 9, 1194-1198.
68. Rampling, R.; Cruickshank, G.; Papanastassiou, V.; Nicoll, J.; Hadley, D.; Brennan, D.; Petty, R.; MacLeam, A.; Harland, J.; McKie, E.; Mabbs, R.; Browm, M. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 2000, 7, 859-866.
69. Papanastassiou, V.; Rampling, R.; Fraser, M.; Petty, R.; Hadley, D.; Nicoll, J.; Harland, J.; Mabbs, R.; Brown, M. The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther., 2002, 9, 398-406.
70. Harrow, S.; Papanastassiou, V.; Harland, J.; Mabbs, R.; Petty, R.; Fraser, M.; et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther., 2004, 11, 1648-1658.
71. Nemunaitis, J.; Khuri, F.; Ganly, I.; Arseneau, J.; Posner, M.; Vokes, E.; Kuhn, J.; McCarty, T.; Landers, S.; Blacknurn, A.; Romel, L.; Randlev, B.; Kaye, S.; Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 2001, 19, 289-298.
72. Bischoff, J.R.; Kirn, D.H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 1996, 274, 342-343.
73. Chiocca, E.A.; Abbed, K.M.; Tatter, S.; Louis, D.N.; Hochberg, F.H.; Barker, F.; Kracher, J.; Grossman, S.A.; Fisher, J.D.; Carson, K.; Rosenblum, M.; Mikkelsen T.; Olson, J.; Markert, J.; Rosenfeld, S.; Nabors, L.B.; Brem, S.; Phuphanich, S.; Freeman, S.; Kaplan, R.; Zwiebel, J. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther., 2004, 10, 958-966.
74. Jiang, H.; Gomez-Manzano, C.; Lang, F.F.; Alemany, R.; Fueyo, J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr. Gene Ther., 2009, 9, 422-427.
75. Khuri, F.R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I.F.; Romel, L.; et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 2000, 6, 879-885.
76. Kumar, S.; Gao, L.; Yeagy, B.; Reid, T. Virus combinations and chemotherapy for the treatment of human cancers. Curr. Opin. Mol. Ther., 2008, 10, 371-379.
77. Rhines, L.D.; Sampath, P.; DiMeco, F.; Lawson, H.C.; Tyler, B.M.; Hanes, J.; et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery, 2003, 52, 872-880.
78. Rustamzadeh, E.; Low, W.C.; Vallera, D.A.; Hall, W.A. Immunotoxin therapy for CNS tumor. J. Neurooncol., 2003, 64, 101-116.
79. Baxter, L.T.; Jain, R.K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res., 1989, 37, 77-102.
80. Bankiewicz, K.S.; Eberling, J.L.; Kohutnicka, M.; Jagust, W.; Pivirotto, P.; Bringas, J.; Cunningham, J.; Budinger, T.F.; Harvey-White, J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys, in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol., 2000, 164, 2-14.
81. Nilaver, G.; Muldoon, L.L.; Kroll, R.A.; Pagel, M.A.; Breakefield, X.O.; Davidson, B.L.; Weissleder, R.; Neuwelt, E. A. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA, 1995, 92, 9829-9833.
82. Kunwar, S.; Chang, S.; Westphal, M.; Vogelbaum, M.; Sampson, J.; Barnett, G.; Shaffrey, M.; Ram, Z.; Piepmeier, J.; Prados, M.; Croteau, D.; Pedain, C.; Leland, P.; Husain, S.R.; Joshi, B.H.; Puri R.K. Phase III randomized trial of CED of IL13-PE38QQR vs. Gliadel wafers for recurrent glioblastoma. Neuro Oncol., 2010, 12, 871-881